3-氨基-5-甲基-1,2,4-噻二唑 | 27182-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氨基-5-甲基-1,2,4-噻二唑
• 英文名称: 5-methyl-1,2,4-thiadiazol-3-amine
• 英文别名: 3-Amino-5-methyl-1,2,4-thiadiazol
• CAS: 27182-55-4
• 化学式: C₃H₅N₃S
• 分子量: 115.159
• InChiKey: XJTJCIZGMCJHTI-UHFFFAOYSA-N

物化性质

• 熔点：
  138-139 °C(Solv: benzene (71-43-2))
• 沸点：
  261.2±23.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氨基-5-甲基-1,2,4-噻二唑 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 、 乙腈 为溶剂， 以43.81 %的产率得到3-iodo-5-methyl-1,2,4-thiadiazole
  参考文献：
  名称：

  [EN] INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF
  [FR] INHIBITEURS DE FACTEURS DU COMPLÉMENT ET UTILISATIONS ASSOCIÉES

  摘要：

  Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

  公开号：

  WO2023137166A1
• 作为产物：
  描述：

  N¹-Acetyl-N³-thioacetylguanidin 生成 3-氨基-5-甲基-1,2,4-噻二唑
  参考文献：
  名称：

  Junge,B., Justus Liebigs Annalen der Chemie, 1975, p. 1961 - 1966

  摘要：

  DOI：

文献信息

• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• [EN] TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012006760A1

  公开（公告）日：2012-01-19

  The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.

  本发明描述和声明了结构式（I）、结构式（II）或结构式（III）的化合物。在结构式（I）中，R1、R2、R3和R3'为-H或甲基，或R3和R3'一起形成双键，或R3'为-H且R2和R3一起形成螺环丙基取代基，R4为-H或-F，R5为-H、甲基、-Cl或-Br。在结构式（II）中，R1为-H、乙基、异丙基、环丙基、甲基或甲氧基，R4为-H或-F，“Y”为：（a）-CH2-；（b）-CR6H-O-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（c）-CR6H-N（R9）-CR7R8-，其中R6、R7和R8独立地为-H或甲基；（d）-CH2-C（R9）（R10）-C（R7）（R8）-，其中R7、R8、R9和R10独立地为-H或-甲基，或R7和R8都为-F，R9和R10独立地为-H或-甲基，或R9和R10都为-F，或R9和R10一起为（O=），与它们连接的碳一起形成羰基。
• NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Boléa Christelle

  公开号：US20130210809A1

  公开（公告）日：2013-08-15

  The present invention relates to novel compounds of Formula (1), wherein M, A and B are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors-subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（1）的新化合物，其中M，A和B如式（I）中所定义; 发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物和使用这些化合物制造药物的用途，以及使用这些化合物预防和治疗mGluR4参与的疾病的用途。
• [EN] NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS DE 2-AMINO-4-PYRAZOLYL-THIAZOLE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：ADDEX PHARMACEUTICALS SA

  公开号：WO2012009009A3

  公开（公告）日：2014-04-03
• [EN] TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS DU GLUTAMATE MÉTABOTROPIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012008999A3

  公开（公告）日：2014-03-27